_DSC0358-2d.jpg
EditedCropped_medium60.jpg
Sensor-på-finger20140404.jpg
Team_placeholderCompr.jpg
_DSC0358-2d.jpg

Glucose control


Glucose control results in reduced mortality, complication rate and hospital costs     

SCROLL DOWN

Glucose control


Glucose control results in reduced mortality, complication rate and hospital costs     

Interested in joining us? We're now hiring - read more here.

Glucose Control

 
improvedcare
 

IMPROVED PATIENT CARE

High or low blood glucose increases the risk of death or complications. Normalizing glucose improves outcomes, if harmful extremes can be avoided.

 
reducedcosts
 

REDUCED ICU COSTS

Reducing length of stay and complications has a significant and beneficial impact on the costs of the intensive care units (ICU).

 
anunsolvedproblem
 

AN UNSOLVED PROBLEM

Over $500 million has been spent trying to make continuous glucose monitoring possible in the ICU, but the problem remains unsolved. 

EditedCropped_medium60.jpg

Product


GlucoSet enables normal blood glucose in ICU patients with its high accuracy, especially in the hypoglycemic range

SCROLL DOWN

Product


GlucoSet enables normal blood glucose in ICU patients with its high accuracy, especially in the hypoglycemic range

Product

 
minimallyinvasive
 

MINIMALLY INVASIVE

By accessing through an indwelling arterial catheter without disrupting that catheter's current use, the GlucoSet sensor requires no new catheters and displaces no other equipment. 

 
reliable
 

RELIABLE

The arterial access makes the GlucoSet sensor less susceptible to coagulation and sensitivity to intravenous nutrition. Unlike competing solutions, the sensor also tolerates patient movement very well.  

 
easytoadopt
 

EASY TO ADOPT

The product can be set up by nurses without advance planning, available in minutes after the decision has been made to monitor glucose.  

An indwelling vascular sensor, particularly one as accurate as [the GlucoSet prototype], should be viewed as a significant advancement.
— Inzucchi & Kosiborod, editors of Anesthesiology in 2011, on published GlucoSet data

The GlucoSet continuous blood glucose monitoring is currently in development, currently in the preclinical stage. Read more about the technology here.

Sensor-på-finger20140404.jpg

Technology


A flexible technology platform that is scalable and based on strong IPR

SCROLL DOWN

Technology


A flexible technology platform that is scalable and based on strong IPR

Technology

 
size
 

Unprecedented SMALL

With a sensor cross sectional area under 5% of the smallest competing product, GlucoSet is the first sensor able to access through arterial catheters without risk.

 
lowcomplexity
 

LOW COMPLEXITY

With a simple system design that relies on few and commercially available components, the GlucoSet system is optimized for low-cost mass production.

 

 

 
IPR
 

STRONG IPR

GlucoSet's technology platform and the manufacturing process is covered by granted patents, and the company is actively expanding the patent portfolio.

 

Team_placeholderCompr.jpg

About us


The team consists of dedicated specialists, experienced medtech entrepreneurs and international experts.

SCROLL DOWN

About us


The team consists of dedicated specialists, experienced medtech entrepreneurs and international experts.

About us

Executive team

DEDICATED SPECIALISTS

The GlucoSet core team has both expert researchers and the necessary understanding of the medical field. Through seasoned technical advisors, the team has access to years of know-how and knowledge. 

Board

ACCOMPLISHED ENTREPRENEURS

The board members contribute to the company with years of experience from medtech entrepreneurship and business development.

Advisory board

INTERNATIONAL EXPERTS

The advisory board consists of international experts within their fields, either as clinical experts or in medtech business development.


Need to get in touch with us? Use the contact form.